Wreghitt T G, Hakim M, Gray J J, Kucia S, Wallwork J, English T A
Clinical Microbiology and Public Health Laboratory, Addenbrooke's Hospital, Cambridge.
J Clin Pathol. 1988 Jun;41(6):660-7. doi: 10.1136/jcp.41.6.660.
Of the first 166 heart and 15 heart and lung transplant recipients at Papworth Hospital, Cambridge, who survived for more than one month after transplantation, 162 were investigated for cytomegalovirus (CMV) infection by serological methods. Altogether, 73 (45%) developed CMV infection after transplantation: 30 (18.5%) had acquired primary infection and 43 (26.5%) reactivation or reinfection. Six patients died of primary infection, probably acquired from the donor organ. Recipients negative for CMV antibody who received an organ from an antibody positive donor had the most severe disease. Heart and lung transplant recipients experienced more severe primary CMV infection than those in whom the heart alone was transplanted. The most sensitive and rapid serological method was a mu-capture enzyme linked immunosorbent assay (ELISA) for detecting CMV specific IgM, the amount of which was often of prognostic value and influenced the management of patients.
在剑桥帕普沃思医院接受心脏移植的首批166例患者以及心肺联合移植的15例患者中,有162例在移植后存活超过1个月,并通过血清学方法对其进行了巨细胞病毒(CMV)感染调查。总共有73例(45%)在移植后发生了CMV感染:30例(18.5%)获得了原发性感染,43例(26.5%)发生了再激活或再次感染。6例患者死于原发性感染,可能是从供体器官获得的。接受来自抗体阳性供体器官的CMV抗体阴性受者病情最为严重。心肺联合移植受者比单纯心脏移植受者经历了更严重的原发性CMV感染。最灵敏、快速的血清学方法是用于检测CMV特异性IgM的微捕获酶联免疫吸附测定(ELISA),其含量通常具有预后价值并影响患者的治疗管理。